Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants

Bin Tu; Huiyuan Wang; Xinran An; Jingkun Qu; Qianqian Li; Yanrong Gao; Mingjie Shi; Hong Qiu; Yongzhuo Huang

doi:10.1016/j.apsb.2022.01.019

Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants

Acta Pharm Sin B. 2022 Jul;12(7):3187-3194. doi: 10.1016/j.apsb.2022.01.019. Epub 2022 Feb 11.

Authors

Bin Tu^{1

2}, Huiyuan Wang¹, Xinran An^{1

3}, Jingkun Qu^{1

4}, Qianqian Li^{1

5}, Yanrong Gao^{1

2}, Mingjie Shi¹, Hong Qiu¹, Yongzhuo Huang^{1

2

6

7

8}

Affiliations

¹ State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
² University of Chinese Academy of Sciences, Beijing 100049, China.
³ University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA.
⁴ School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
⁵ Nanchang University College of Pharmacy, Nanchang 330006, China.
⁶ Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528437, China.
⁷ NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients, Shanghai 201203, China.
⁸ Taizhou University, School of Advanced Study, Institute of Natural Medicine and Health Product, Taizhou 318000, China.

Abstract

The heparin polysaccharide nanoparticles block the interaction between heparan sulfate/S protein and inhibit the infection of both wild-type SARS-CoV-2 pseudovirus and the mutated strains through pulmonary delivery.Image 1.

Keywords: Delta variant; Heparan sulfate; Heparin nanoparticle; Pulmonary delivery; SARS-CoV-2; Spike protein.